Nature Communications (Feb 2021)
Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody
- Ronit Rosenfeld,
- Tal Noy-Porat,
- Adva Mechaly,
- Efi Makdasi,
- Yinon Levy,
- Ron Alcalay,
- Reut Falach,
- Moshe Aftalion,
- Eyal Epstein,
- David Gur,
- Theodor Chitlaru,
- Einat B. Vitner,
- Sharon Melamed,
- Boaz Politi,
- Ayelet Zauberman,
- Shirley Lazar,
- Adi Beth-Din,
- Yentl Evgy,
- Shmuel Yitzhaki,
- Shmuel C. Shapira,
- Tomer Israely,
- Ohad Mazor
Affiliations
- Ronit Rosenfeld
- Israel Institute for Biological Research
- Tal Noy-Porat
- Israel Institute for Biological Research
- Adva Mechaly
- Israel Institute for Biological Research
- Efi Makdasi
- Israel Institute for Biological Research
- Yinon Levy
- Israel Institute for Biological Research
- Ron Alcalay
- Israel Institute for Biological Research
- Reut Falach
- Israel Institute for Biological Research
- Moshe Aftalion
- Israel Institute for Biological Research
- Eyal Epstein
- Israel Institute for Biological Research
- David Gur
- Israel Institute for Biological Research
- Theodor Chitlaru
- Israel Institute for Biological Research
- Einat B. Vitner
- Israel Institute for Biological Research
- Sharon Melamed
- Israel Institute for Biological Research
- Boaz Politi
- Israel Institute for Biological Research
- Ayelet Zauberman
- Israel Institute for Biological Research
- Shirley Lazar
- Israel Institute for Biological Research
- Adi Beth-Din
- Israel Institute for Biological Research
- Yentl Evgy
- Israel Institute for Biological Research
- Shmuel Yitzhaki
- Israel Institute for Biological Research
- Shmuel C. Shapira
- Israel Institute for Biological Research
- Tomer Israely
- Israel Institute for Biological Research
- Ohad Mazor
- Israel Institute for Biological Research
- DOI
- https://doi.org/10.1038/s41467-021-21239-8
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 9
Abstract
Here, using the K18-hACE2 transgenic mice model, the authors report the in vivo efficacy of a fully human neutralizing antibody against SARS-CoV-2 and show that when administered before or up to 3 days post infection, treated mice do not exhibit disease symptoms while 80% of control animals succumb to the infection.
